# Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

> **NCT02757248** · PHASE1 · WITHDRAWN · sponsor: **Anne Beaven, MD**

## Conditions studied

- PTCL
- CTCL

## Interventions

- **DRUG:** Volasertib
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT02757248
- **Lead sponsor:** Anne Beaven, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Boehringer Ingelheim is discontinuing their volasertib development program
- **Last updated:** 2016-12-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757248, "Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02757248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*